Evidence map›Paper›PMID 29618644›Full record

ArticleJournal of virology2018

Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11.

Thandeka Moyo, June Ereño-Orbea, Rajesh Abraham Jacob, Clara E Pavillet, Samuel Mundia Kariuki, Emily N Tangie, Jean-Philippe Julien, Jeffrey R Dorfman

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Topological analysis of the gp41 MPER on lipid bilayers relevant to the metastable HIV-1 envelope prefusion state.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Thandeka MoyoDivision of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
June Ereño-OrbeaProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
Rajesh Abraham JacobDivision of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Clara E PavilletProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
Samuel Mundia KariukiDivision of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Emily N TangieDivision of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Jean-Philippe JulienProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
Jeffrey R DorfmanDivision of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa jeffrey.dorfman@uct.ac.za.ORCID https://orcid.org/0000-0001-9938-8911
University of Cape Town · ZAUniversity of Toronto · CAHospital for Sick Children · CA

Funding

Time resolved SAXS studies on the RP2/Arl3 complex pp.484-485P41GM103622 · NIGMS · ILLINOIS INSTITUTE OF TECHNOLOGY · PI IRVING, THOMAS C · 2012 to 2020
$11.9M
CIHRNIGMS NIH HHS P41 GM103622
6 · The paper itself

Abstract

Understanding the mechanisms used by HIV-1 to evade antibody neutralization may contribute to the design of a high-coverage vaccine. The tier 3 virus 253-11 is poorly neutralized by subtype-matched and subtype C sera, even compared to other tier 3 viruses, and is also recognized poorly by V3/glycan-targeting monoclonal antibodies (MAbs). We found that sequence polymorphisms in the V3 loop and N-linked glycosylation sites contribute only minimally to the high neutralization resistance of 253-11. Interestingly, the 253-11 membrane-proximal external region (MPER) is rarely recognized by sera in the context of the wild-type virus but is commonly recognized in the context of an HIV-2 chimera, suggesting steric or kinetic hindrance of binding to MPER in the native envelope (Env). Mutations in the 253-11 MPER, which were previously reported to increase the lifetime of the prefusion Env conformation, affected the resistance of 253-11 to antibodies targeting various epitopes on HIV-1 Env, presumably destabilizing its otherwise stable, closed trimer structure. To gain insight into the structure of 253-11, we constructed and crystallized a recombinant 253-11 SOSIP trimer. The resulting structure revealed that the heptad repeat helices in gp41 are drawn in close proximity to the trimer axis and that gp120 protomers also showed a relatively compact disposition around the trimer axis. These observations give substantial insight into the molecular features of an envelope spike from a tier 3 virus and into possible mechanisms that may contribute to its unusually high neutralization resistance.

Indexed as

Amino Acid SequenceAntibodies, MonoclonalAntibodies, NeutralizingEpitopesHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHumansPolymorphism, GeneticPolysaccharidesAntibodies, MonoclonalAntibodies, NeutralizingEpitopesHIV AntibodiesHIV Envelope Protein gp120PolysaccharidesantibodyHIV-1HIV-1 vaccineneutralization

Identifiers

PMID29618644
PMCPMC6026760
OpenAlexW2795896160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.